Biochemical Outcome in Metastatic Prostate Cancer Patients Following Prostate-Directed Radiotherapy

Author:

Ayoub Heba Maged1,Zamzam Maha Lotfy1,Elsayed Fifi Mostafa1,Hassanin Ihab Mohammed1,Elsemary Eman Essam1

Affiliation:

1. Suez Canal University

Abstract

Abstract Background The role of cytoreductive local radiotherapy (RT) in metastatic prostate cancer has recently been established. This study aimed to evaluate the biochemical outcome of local RT in metastatic prostate cancer. Methods This randomized controlled phase III study was conducted at the Clinical Oncology Department, Suez Canal University Hospital. Eligible participants were de-novo or metachronous metastatic prostate cancer patients with Eastern Cooperative Oncology Group performance status of 0–2. Participants were randomized to receive either cytoreductive prostate-directed RT in addition to standard care or standard care alone. The conventional radiation schedule of 70 Gy/35 fractions or the hypofractionated schedule of 55 Gy/20 fractions were delivered. The primary endpoint was biochemical progression-free survival (BPFS), and secondary endpoints included clinical response, and overall survival (OS). Survival and post-hoc analyses were performed using Cox regression and the Kaplan-Meier method with the log-rank test. Results Between November 23, 2020, and November 21, 2022, 70 patients were enrolled in this study. Of them, 34 patients were assigned to the prostate radiotherapy group, and 29 patients were assigned to the control group. At a median follow-up of 12 months, the median BPFS has not been reached for the prostate radiotherapy group compared to 4.067 months for the control group (HR: 0.147, p < 0.001). Subgroup analysis showed that the median BPFS was statistically significantly correlated with low-volume (95% CI, 0.004 to 0.262, p = 0·001) and hormonal-sensitive metastatic disease (95% CI, 0.010 to 0.192, p < 0·001). The median OS was 16.33 months for the prostate-radiotherapy group compared to 11.33 months for the control group (HR: 0.313, p = 0.003). Conclusion Prostate-directed RT improved BPFS and OS in metastatic prostate cancer patients, particularly in those with low volume and hormonal-sensitive disease. Trial Registration: This trial is registered on (27/4/2023) with pactr.samrc.ac.za, PACTR202305854600529, URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=25510

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3